Phlexglobal Acquires Cunesoft

Reviva Pharmaceuticals and the FDA have reached alignment on the 4-week global registrational study.

In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.

Imfinzi (durvalumab; AstraZeneca) plus gemcitabine and cisplatin was found to double the overall survival rate after three years in patients with advanced biliary tract cancer.

In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.

Columvi with gemcitabine and oxaliplatin showed the potential to improve survival in patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

Following a webinar on what the clinical trials space will look like for the remainder of 2024, ACT caught up with Getz and Murphy to discuss their biggest takeaways.